Directory · AU
Biotechnology Research in Australia
A register of firms and the professionals working at them in the Biotechnology Research sector based in Australia. Browse the public index, then filter or export on Kipplo.
Companies
575 on file
Burnet Institute
Burnet is an Australian-based medical research institute and an accredited international non-government organisation. We undertake life-changing research and health programs in the Indo-Pacific region and Africa. Everything we do is about one fundamental goal: a better, fairer, healthier world, with no-one left behind. Burnet works globally, with offices in Australia, Myanmar, Papua New Guinea and Vanuatu. Learn more at: burnet.edu.au Interested in working at Burnet? Visit: burnet.edu.au/careers
501 to 1000 staff
Agbitech
For nearly 20 years, AgBiTech has been on a mission to make pest management more sustainable and farming more profitable. As the world’s leading producer of NPV-based insecticides, we apply our expertise in research, field development and state-of-the art manufacturing to bring our solutions to major row crops around the world. We manufacture all products in-house at our global headquarters in Fort Worth, TX. Our relentless focus on quality and efficiency, allows us to produce consistent and cost effective biological products that have established us as the market leader in NPV production and commercialization. For further information, visit
11 to 50 staff
Clarity Pharmaceuticals
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
51 to 200 staff
Invetech
At Invetech, we bring your innovations to life. We are a product realization company that designs, engineers and manufactures fully customizable platforms, tailored to our clients’ needs. Our mission is to push the boundaries of what’s possible in health and life sciences in close collaboration with our clients and leveraging our deep domain expertise. We are passionate about transforming groundbreaking ideas into business successes, specializing in custom engineering solutions that power the next generation of diagnostics and cell therapies. From cutting-edge instrument development and contract manufacturing to single-use consumables, we offer comprehensive solutions that support innovation at every stage. We are an independent, privately held company with a long history of operating in large, global and public companies such as Danaher and Fortive.
201 to 500 staff
Shimadzu Corporation
Shimadzu Corporation has remained committed to commercializing cutting-edge technology and providing it to customers in a wide array of industries for more than 150 years. Our brand statement,"Excellence in Science", reflects our desire and attitude to diligently respond to customers' requirements by offering superior, world-class analytical and measuring instruments, medical imaging systems, aircraft equipment and industrial machinery for the advancement of human health, the safety and security of society, and industrial processes. In today’s challenging, ever-changing landscape, Shimadzu aims to partner with customers to meet their needs with unique technologies and solutions.
10001+ staff
Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®.
11 to 50 staff
360biolabs, A Bioagilytix Company
360biolabs is Australia's most comprehensive bioanalytical and specialty laboratory offering science-driven expertise and laboratory services for Phase clinical studies. Our advanced laboratories in Melbourne and Brisbane, specialise in using cutting-edge thinking and technology to support the development of novel therapeutics, vaccines and diagnostics. Our global team has laboratories in both the United States and Europe. With our every sample counts mindset, our meticulous attention to detail and adherence to global scientific standards under GLP, GCP and ISO17025 – ensuring the highest level of quality in every clinical trial we undertake. Our quality systems drive method development, tech transfer and assay validation, compliant with ICH, FDA and EMA. 360biolabs has an experienced team of scientists able to conduct a wide array of assays and offers diverse specialist services. Examples include: Pharmacokinetics (PK), Pharmacodynamics (PD), LC/MS, Flow Cytometry, Biomarkers, Molecular Assays, Virology, Central Laboratory services (kit production and lab manuals).__ Follow along in our journey enabling future medicines, or contact our team to learn more about our service offerings and get proposal estimates. Learn more at 360biolabs.com Get in touch via email at: bd@360biolabs.com
51 to 200 staff
Cell Therapies Pty Ltd
Cell Therapies Pty Ltd is a contract development and manufacturing organization (CDMO) that manufactures and deploys advanced cell-based therapies to the global market. Established in 2003, Cell Therapies is one of the most experienced GMP compliant manufacturers of cell therapies, gene therapies, cellular immunotherapies, and regenerative medicine products globally. We have a 13-cleanroom GMP facility that meets global regulatory and international organisation for standardisation (ISO) standards benchmarked by the Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S). Our services cover the complete manufacturing process from development to deployment, providing needle-to-needle control with clinical integration. Our facility is co-located with the Peter MacCallum Cancer Centre in Melbourne, Australia, providing access to hospitals, research institutes, and universities to support product development, translation to the clinic, and patient access. Please contact us through our website to discuss potential collaborations.
51 to 200 staff
Genetic Signatures
Genetic Signatures is an established, global molecular diagnostics company, specialising in syndromic multiplex real-time PCR testing to provide configurable, clinically relevant MDx solutions for infectious diseases. A diverse range of assays are available under the EasyScreen™ brand, for the flexible detection of over 100 pathogens impacting global health. The EasyScreen™ kits are underpinned by Genetic Signatures’ innovative 3base™ technology, which transforms natural genetic sequences into a 3base™ sequence of A, T and C which improves multiplex efficiency and reduces the genetic complexity of detecting pathogens. This is particularly beneficial for detecting pathogen subtypes and providing increased resistance to mutation or variants, such as SARS-CoV-2. Genetic Signatures’ flexible syndromic approach provides a timely and accurate diagnosis that enhances efficiencies within the laboratory. Customers trust Genetic Signatures’ assay and workflow reliability which is supported by the Company’s high service standards and genuine partnership for driving improved patient outcomes. Genetic Signatures’ EasyScreen™ products are accessible in over 30 countries, with direct representation in the United States, United Kingdom, Germany, and Australia, and distribution partners in Canada, South America, Africa and other European nations. Products are used for IVD use and research purposes. As an employer, Genetic Signatures is proud of their highly rated and diverse workplace culture, and is committed to providing equal employment opportunities and professional development. Visit for more information or email marketing@geneticsignatures.com to contact your local specialist.#moleculardiagnostics #pathology #PCR #multiplex #infectiousdisease #3base
51 to 200 staff
Ingham Institute For Applied Medical Research
Ingham Institute for Applied Medical Research is the pre-eminent medical research institute of South Western Sydney. We have local purpose, national significance, and global impact. Join us in inspiring better health and transforming the treatment and care of people living with the most prevalent medical conditions and diseases.
201 to 500 staff
Lucas Meyer Cosmetics - By Clariant
Lucas Meyer Cosmetics develops, manufactures and markets innovative ingredients for the cosmetic and personal care industry. We offer active ingredients, functional ingredients and delivery systems from various origins.
51 to 200 staff
Pictor
Providing researchers, diagnostics manufacturers, clinical labs, and vet clinics a streamlined and cost-effective multiplex proteomics platform that delivers multiple biomarker insights simultaneously across diverse sample types, offering a more flexible and efficient alternative to singleplex assays and large-scale proteomics solutions.
11 to 50 staff
Universal Biosensors
Universal Biosensors entered voluntary administration in August 2025, with Triton Biosensors — part of Triton Holdings — acquiring the majority of its assets in October 2025. Triton Biosensors has now commenced manufacturing of the Sentia™ and Xprecia™ product lines and is committed to continuing the legacy and quality of these exceptional products. To stay informed about the latest developments, product updates, and company news, please follow the Triton Biosensors LinkedIn page:
51 to 200 staff
Integrated Sciences
Integrated Sciences, established in 1983, is a privately owned Australian company specialising in the sale and support of Clinical Diagnostics, Molecular Diagnostics, Point of Care and Research products to the Australian and New Zealand markets. Our success has stemmed from our ability to understand our customers needs and partnering with innovative and reliable International suppliers. Our company motto "Our Strategy is Support" exemplifies our focus and recognises the support and skills of our staff in enabling our success.
11 to 50 staff
Neogen Food Safety, Australasia
Neogen Australasia, based in Ipswich, Queensland is a subsidiary of Neogen Corporation (NASDAQ: NEOG). Neogen provides the most comprehensive range of solutions for the food processing, animal protein and agriculture industries, not only protecting the world’s food supply, but also allowing our customers to produce more efficiently and effectively than they could before. Our Food Safety product range covers solutions for the Australasian Agribusiness sector including dehydrated culture media and rapid diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, plant diseases, and hygiene indicators through ATP sanitation monitoring and much more. Megazyme, a major supplier of diagnostic products such as reagents, enzymes and assay kits for quality management of nutritional analysis and research, was acquired by Neogen in 2021. Megazyme are world leaders in the measurement of dietary fiber components, starch, sugars, polysaccharides, and enzymes which dictate the quality of the final product. Within Australia and New Zealand, Megazyme test kits are supplied to commercial and research labs, processed food and beverage manufacturers, cereal and dietary fiber, dairy and infant formula industries, winemaking, malting, brewing & distilling, animal and pet food industries. Neogen’s Australasia's Genomics division is the region’s largest genomic testing facility in Queensland. We offer livestock producers bespoke livestock DNA Testing solutions to make educated breeding decisions that improve the efficiencies of their herds, breed associations to verify parentage.
51 to 200 staff
Tsi Group
Lead the Supplement Industry Revolution — Join TSI in Building a Healthier Future Why Now? TSI Group has just reached a defining milestone — our successful listing on the Shanghai Stock Exchange Main Board (JYJT: 603262). This marks not only recognition of our 29 years of innovation, credibility, and financial strength, but also the beginning of our most ambitious growth chapter yet. Backed by strong global demand and fresh capital investment, we are scaling our science-driven platform to redefine health and wellness worldwide. Who We Are Since 1996, TSI has been dedicated to improving health, lifestyle, and longevity for people everywhere. From humble beginnings as Ingredients supplier, we’ve grown into a global total solution partners with Innovative and optimized Ingredients, Contract Manufacturing for finish Dosage, and Tailored Script — all driven by science, discovery, and innovation. Our vision is to deliver consumer-centric innovation solutions to our customers, transforming real health needs into accessible, science-backed answers. Watch our story on YouTube and see how you can help us shape the future of global health. Our Impact • Proven Growth: Sustained double-digit growth, grounded in customer focus and innovation. • Innovation Leadership: 228+ global patents and cutting-edge platforms like FZZR™, OptiClear™, and Tailored Script®. • Market Leadership: World’s largest HMB supplier and a premium glucosamine leader. • Total Solutions – From customized ingredients to formulations, powered by our unique Tailored Script® platform. • Global Footprint – Global R&D centers and new manufacturing sites in Thailand, Australia, Hong Kong, the US, and more in China. • Trust & Quality: World-class manufacturing and regulatory excellence.
501 to 1000 staff
Aegros
At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. Our mission is to put the patient first through innovation and we do this thanks to our Australian invented Haemafrac®, Aegros' unique electroseparation process. Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma. Aegros is currently undertaking the final preparations for the submission of a dossier for the registration of this hyperimmune against Covid-19 on the Australian Register of Therapeutic Goods (ARTG) Simultaneously, Aegros is finishing the upgrade of its existing hyperimmune facility at Macquarie Park NSW to be able to process of plasma per year.
51 to 200 staff
Ausbiotech
AusBiotech is Australia's Biotechnology Industry Organisation, dedicated to the development, growth and prosperity of the Australian Biotechnology Industry. We deliver initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for our sector nationally and around the world. AusBiotech represents over members working and studying in life sciences, including therapeutics, medical technology (devices and diagnostics), digital health, and agritech. With representation across the states our national network works to promote Australian research, translation, development, commercialisation and manufacturing in the national interest. The structure is a not-for-profit limited guarantee company managed by a Board elected by members in line with its constitution.
11 to 50 staff
Bionics Institute
The Bionics Institute is an internationally recognised, independent medical research institute that solves medical challenges with technology. We lead the world in the research and development of innovative medical devices and therapies to improve human health. Our multidisciplinary team is comprised of world-class scientists, engineers and researchers, and our laboratories are located in St Vincent’s Hospital Melbourne, close to our clinical collaborators. Together we transform the lives of people with a range of conditions, including Alzheimer’s disease, hearing impairment, vision loss, Crohnʼs disease, Parkinsonʼs disease, stroke, arthritis, incontinence and diabetes. The Bionics Institute has an impressive track record of translating medical device concepts into clinical reality dating back to 1986 when it was founded by Professor Graeme Clark, leader of the team that created Australiaʼs cochlear implant. Since then, Bionics Institute researchers have developed: • Australiaʼs first-generation bionic eye prototype implanted in clinical trials in 2018- The epilepsy seizure monitoring device Minder™, commercialised through Epi-Minder Pty Ltd- An adaptive deep brain stimulation system for Parkinsonʼs disease, commercialised through Deep Brain Stimulation Technologies Pty Ltd- An innovative vagus nerve stimulation device to treat inflammatory bowel disease, which is moving into clinical trials and also being adapted to treat rheumatoid arthritis and diabetes- Novel drug delivery methods for hearing loss; new diagnostic tools for improved diagnosis of infant hearing. Growth into new areas will build on our expertise in medical device development and a recent expansion of our world-class facilities to include the end-to-end medical device prototype manufacturing facility, Neo-Bionica.
51 to 200 staff
Cell Care Australia
Cell Care is Australia’s largest and most experienced cord blood and tissue stem cell bank. We collect process and store umbilical cord blood and tissue to provide potential medical treatment options for Australian families. At Cell Care we invest in driving market awareness through multiple consumer and health care professional channels. Our clinical trials investment program supports local Australian research into potential new indications for cord blood including type 1 diabetes and cerebral palsy. We are a dynamic and innovative Australian owned company with passionate employees who love what they do.
11 to 50 staff
Mimotopes
For 30 Years, Mimotopes has been a world leader in Custom Peptide Technology and Antibody Production. Mimotopes develops, markets and distributes sophisticated biochemical products and services for the biotech and pharmaceutical industries. Established in Melbourne, Australia in 1989, Mimotopes now has a global customer base with sales offices and distribution channels in the US, UK, Europe, Japan and India. Mimotopes uses proprietary technologies in solid phase synthesis, molecule scavenging applications and biomolecular capture and immobilisation. Coupled with the extensive experience and expertise of its staff, Mimotopes has become one of the global leaders in its field. Mimotopes is the inventor of Peptide Library Technology, Synphase Quantitative Solid Phase Chemistry System, and REPLi off-the -shelf Protease Profiling Technology. Mimotopes provides great before and after sale service. Post graduate friendly!
11 to 50 staff
Provectus Algae
Provectus Algae is a biotechnology company specializing in the optimization of algae & microalgae species to produce high-value biobased chemicals, specialty ingredients, and biologics. Importantly, Provectus Algae uses photosynthetic bioprocesses to transform light and carbon dioxide into critical bioproducts. Provectus Algae’s end-to-end biomanufacturing platform, powered by its Precision Photosynthesis™ technology, has far-reaching applications in a variety of industries, including agriculture, food and beverage aquaculture, cosmetics & personal care, pharmaceuticals, and beyond. Algae biotechnology holds tremendous industrial potential thanks to Algae’s impressive biochemical diversity, sophisticated biosynthesis machinery, and rapid growth rates. Photosynthetic Algae species also provide the life science community with a powerful mechanism for reducing carbon footprint and improving sustainability. Provectus Algae built its biomanufacturing platform to take Algae-based products from discovery to large-scale production, actualizing the full potential of algae biotechnology. We have brought together the combined strengths of our talented multidisciplinary team to rapidly build scalable algae production systems and source high-value compounds for our partners. Provectus Algae enables these groundbreaking capabilities with a well-balanced fusion of innovative proprietary technology and a thorough knowledge of the unique biological traits of algae. By leveraging advanced automation, machine learning, and synthetic biology approaches, Provectus Algae can rapidly develop, execute, and license biomanufacturing processes depending on the needs of our commercial partners. With Provectus Algae our partners enjoy: 1). Rapid Speed to Market Through End-to-End Supply Solutions 2). Environmentally Sustainable Biomanufacturing 3). Novel Natural and Synthetic Biology Products from Algae Start making your molecules using light and CO2 today!
11 to 50 staff
Southern Star Research
Sydney-based CRO Southern Star Research can access the financial, operational and regulatory advantages of conducting clinical trials in Australia. This local knowledge, as well as our full-service offering, enables our biotechnology, pharmaceutical and medical device customers to benefit from the Australian environment. We have expertise in a broad range of indications, and a Clinical Team who have an average of 17 years direct clinical research experience. Furthermore, all of our work is underpinned by a passion for cutting edge science, a keen interest in early stage clinical development and a willingness to provide every client with exceptional customer service. With a track record of success in clinical trials spanning Phase I to IV, Southern Star Research has both the capability and the drive to support your R&D objectives in Australia and Asia-Pacific.
51 to 200 staff
Biosensis Pty Ltd
Biosensis specializes in antibodies and reagents for Neuroscience. Our neuroscience portfolio includes products for research in neurodegenerative diseases, neurodevelopment,and neuro-metabolism. Areas of focus include Alzheimer's, Parkinson's and ALS diseases, as well as autophagy and metabolic and stress disorders including metabolic syndrome research, obesity, and neuroimmunology and inflammation with particular emphasis on neurotrophins and neurotrophin receptors for which Biosensis has been the worldwide leader and OEM supplier for more than 30 years. Biosensis also offers more than 200 high-quality ELISA kits for a wide range of protein targets. Our assays are validated for a variety of sample matrices and where possible, tested by independent research laboratories. Our ELISA kits are complete, ready-to-use and without the need for additional reagents, buffers or plates. Plus our strip format allows you to only use what you need! Our detailed protocols include extensive information about sample preparation, assay execution, data analysis and validation. Full technical support is also provided by our highly skilled technical team at biospeak@biosensis.com. Our new range of RapidTM ELISA assays can be performed in less than 4 hours without compromising on accuracy, specificity and sensitivity. These assays target potential biomarkers, such as oligomeric Aβ peptides (Alzheimer's Disease, AD), mature BDNF (psychiatric disorders), proNGF (cancer) and p75NTR/NGFR (Amytrophic Lateral Sclerosis, ALS). Why purchase from Biosensis? Biosensis is a company formed by a team of life scientists and business people dedicated to the support of researchers in academia and industry worldwide. The team has a combined total of over 50 years experience in the commercialization of life science reagents for the life science research and diagnostic markets. We are therefore able to offer a level of customer support and expertise unmatched in the neuroscience reagent industry.
11 to 50 staff
